ACR: Prolonged Use Of Salagen Safe And Effective For Sjogren’s Syndrome
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ACR: Prolonged Use Of Salagen Safe And Effective For Sjogren’s Syndrome

MINNEAPOLIS, MI -- November 15, 1999 -- MGI PHARMA, Inc. reported that Salagen(R) Tablets (pilocarpine hydrochloride) retains its pharmacologic effect even after prolonged use, according to data presented at the 63rd Annual Convention of the American College of Rheumatology (ACR) being held in Boston. In addition, data from another study presented at the ACR meeting showed that individual Sjogren's syndrome-like symptoms exist widely in adult women.

Dr. Francis LeVeque, Director of Oral Medicine and Oral Surgery at Harper-Grace Hospital in Detroit, MI presented data from an abstract entitled "Sustained Increases in Salivary Flow and Safety Findings Following Extended Use of Pilocarpine Tablets for the Treatment of Dry Mouth Symptoms in Patients with Sjogren's Syndrome." The abstract concluded the following:

-- Prolonged use of Salagen Tablets (pilocarpine hydrochloride) does not lead to loss of their pharmacologic effect and
-- Prolonged use of Salagen Tablets is safe and well tolerated.

Dr. Frederick Vivino, Thomas Jefferson University Clinical Associate Professor of Medicine, presented data from a second abstract entitled "Prevalence of Sjogren's Syndrome-Like Symptoms in the Adult Female Population." This abstract concluded the following:

-- Individual symptoms suggestive of Sjogren's syndrome are highly prevalent in the "normal" female population, but seldom reported to physicians and
-- Greater patient and physician awareness of Sjogren's syndrome and its consequences is needed to facilitate earlier diagnosis.

The U.S. Food and Drug Administration approved Salagen Tablets for the treatment of xerostomia (dry mouth) associated with Sjogren's syndrome in February 1998. Studies demonstrate that the drug works by stimulating the exocrine glands, including the salivary glands, to increase their activity.

Sjogren's syndrome is a chronic, inflammatory, autoimmune disease that gradually damages the body's moisture-producing glands, including the salivary glands, causing patients to suffer significantly from the resulting dryness. Symptoms of the disease can include dry mouth, dry eyes, dry skin, and vaginal dryness, depending upon which moisture-producing glands are affected and to what degree the glands are damaged. Left untreated, Sjogren's syndrome can ultimately affect the neurological, muscular and gastrointestinal systems.

Releted Links: Salagen(R) Tablets (pilocarpine hydrochloride) and MGI PHARMA, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities